Phase 3 Immune Checkpoint Inhibitor Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 3
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting
Phase 3
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Radiotherapy, AdjuvantHepatocellular Carcinoma (HCC)Immune Checkpoint Inhibitor+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences286 enrolled1 locationNCT07186621